Last updated on August 2018

Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: chronic phase chronic myelogenous leukemia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. 18 years at the time of Ph+ CP-CML diagnosis
  2. Newly diagnosed chronic phase of Ph+ CP-CML, confirmed with cytogenetic and/or molecular testing at baseline
  3. Treatment-nave and initiating treatment with dasatinib, imatinib, or nilotinib
  4. Willingness and ability to comply with routine office visits

Exclusion Criteria:

  1. Any other prior or active non-CML active malignancy for which the patient is receiving treatment
  2. Participation in a therapeutic clinical trial for CML disease

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.